Spotlight Innovation Enters 2017 On Strong Footing

Recent Highlights Include a Strategic Investment in SOLX and an Exclusive Right with FSU to Fight Zika Virus

SANTA MONICA, CA / ACCESSWIRE / January 12, 2017 / Online Media Group Covers Spotlight Innovation (STLT). Spotlight Innovation, a pharmaceutical company advancing technologies to address rare, emerging, and neglected diseases, recently announced that it had obtained an exclusive, worldwide right from the Florida State University Research Foundation to develop and commercialize a therapy to combat the Zika virus, a mosquito born virus which continues to cause major concern in the United State and abroad, particularly in South Florida the epicenter of the growing outbreak. Florida State University Research Foundation is one of the premiere institutions leading the fight against Zika, a virus that has proven to cause severe birth defects. The announcement represents a significant milestone for Spotlight Innovation, a company as committed to putting a stop to the havoc wreaked by Zika as it is to identifying unique and profitable opportunities in the medical field.

The license granted by the Florida State University Research Foundation covers more than just a treatment in the fight against Zika. It includes the worldwide, exclusive rights to develop and commercialize certain compounds including those identified in a study1 co-authored by Florida State University Professor, Hengli Tang that was published in Nature Medicine in August of 2016. Prof. Tang and his research team collaborate with Spotlight Innovation as part of an existing sponsored research agreement (SRA). Mr. Tang is also a critical member of the Spotlight’s Scientific Advisory Board.

In addition, Spotlight Innovation also focuses on developing and commercializing STL-182, an orally-available small molecule for the treatment of spinal muscular atrophy; and products derived from snake venom that could provide analgesic relief from moderate to severe chronic pain. In addition, it offers SOLX Gold Shunt, an implantable drainage device designed to reduce elevated intraocular pressure associated with refractory glaucoma without creating a bleb. Spotlight Innovation announced a strategic investment in Solx, Inc., a Massachusetts-based, privately-held medical device company, towards the end of 2016.

Legal Disclaimer: Online Media Group, Inc. is not registered with any financial or securities regulatory authority and does not provide, nor claims to provide, investment advice or recommendations to readers of this release to buy, sell or hold any securities. Investing intrinsically involves substantial risk and readers are reminded to consult an investment professional and complete their own due diligence, including SEC filings, when researching any companies mentioned in this release. This release is based upon publicly available information and, while vetted, is not considered to be all-inclusive or guaranteed to be free from errors. With respect to Section 17(B) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader’s attention to the fact that Financial Press Media Group, Inc. may have received compensation from the companies mentioned in this release.

For further information:

Online Media Group, Inc.
310.413.5788

SOURCE: Online Media Group Inc

ReleaseID: 452632